Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Alden A. Moccia, Emanuele Zucca & Michele Ghielmini. (2017) Is there a role for a maintenance rituximab in indolent lymphoproliferative diseases other than follicular lymphoma?. Leukemia & Lymphoma 58:1, pages 30-36.
Read now
Read now
Paolo Strati, Wei-Gang Tong, Candida Vitale, William G. Wierda, Susan O’Brien, Jennifer R. Brown, Wen-Kai Weng, Thomas Kipps, Michael J. Keating & Alessandra Ferrajoli. (2015) A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia. Leukemia & Lymphoma 56:6, pages 1878-1880.
Read now
Read now
Tadeusz Robak. (2012)
Rituximab for chronic lymphocytic leukemia. Expert Opinion on Biological Therapy 12:4, pages 503-515.
Read now
Read now
Eric van den Neste, Rémi Letestu, Thérèse Aurran-Schleinitz, Loïc Ysebaert, Pierre Feugier, Stéphane Leprêtre & Caroline Dartigeas. (2012) Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?. Leukemia & Lymphoma 53:3, pages 362-370.
Read now
Read now
Alessandra Tedeschi, Eleonora Vismara, Francesca Ricci, Enrica Morra & Marco Montillo. (2010) The spectrum of use of rituximab in chronic lymphocytic leukemia. OncoTargets and Therapy 3, pages 227-246.
Read now
Read now
Articles from other publishers (7)
Tadeusz Robak, Jerzy Błoński, Aleksander Bartłomiej Skotnicki, Magdalena Piotrowska, Tomasz Wróbel, Justyna Rybka, Janusz Kłoczko, Łukasz Bołkun, Bożena Katarzyna Budziszewska, Urszula Walczak, Anatoly Uss, Marta Fidecka & Piotr Smolewski. (2018) Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial. European Journal of Haematology 100:5, pages 465-474.
Crossref
Crossref
Pau AbrisquetaNeus VillamorMaría José TerolEva González-BarcaMarcos GonzálezChristelle FerràEugenia AbellaJulio DelgadoJose A. García-MarcoYolanda GonzálezFelix CarbonellSecundino FerrerEncarna MonzóIsidro JarqueAna MuntañolaMireia ConstantsLourdes Escoda, Xavier CalvoSabela BobilloJosé Bruno Montoro, Emili MontserratFrancesc Bosch. (2013) Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia. Blood 122:24, pages 3951-3959.
Crossref
Crossref
Lindsay AM Rein, Anthony D Sung & David A Rizzieri. (2013) New approaches to manipulate minimal residual disease after allogeneic stem cell transplantation. International Journal of Hematologic Oncology 2:1, pages 39-48.
Crossref
Crossref
André Goy & Susan O’Brien. 2011. Principles and Practice of Cancer Infectious Diseases. Principles and Practice of Cancer Infectious Diseases
47
66
.
Isrid Sturm, Joachim Oertel, Stephan Oertel, Jörg Westermann & Antonio Pezzutto. (2008) Successful long-term monotherapy with rituximab in a patient with chronic lymphocytic leukemia of the B-cell-lineage: a case report. Journal of Medical Case Reports 2:1.
Crossref
Crossref
Robert M. Sharkey & David M. Goldenberg. (2008) Use of antibodies and immunoconjugates for the therapy of more accessible cancers. Advanced Drug Delivery Reviews 60:12, pages 1407-1420.
Crossref
Crossref
. (2008) Current Awareness in Hematological Oncology. Hematological Oncology 26:1, pages 46-53.
Crossref
Crossref